Last reviewed · How we verify
Interrupted apixaban
At a glance
| Generic name | Interrupted apixaban |
|---|---|
| Also known as | Interrupted Eliquis |
| Sponsor | Baim Institute for Clinical Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure (NA)
- DOAC in Chinese Patients With Atrial Fibrillation
- Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry
- Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
- Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation (PHASE4)
- Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot (NA)
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (PHASE3)
- Perioperative Anticoagulant Use for Surgery Evaluation Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |